Abbott Laboratories (ABT) director reports 313 new stock equivalent units

Rhea-AI Filing Summary

Abbott Laboratories director John G. Stratton reported compensation-related activity in company-linked instruments. On 12/31/2025, he acquired 313 stock equivalent units at $125.29 each, recorded as a derivative security tied to Abbott common shares. After this transaction, he beneficially owned 13,034 stock equivalent units directly.

The filing explains that these units represent director fees credited to a stock equivalent unit account in a grantor trust established by the director and are generally paid out in cash at about age 65 or upon retirement from the board. The units earn the same return as if the fees were invested in Abbott shares, and the reported balance also reflects units accumulated through a dividend reinvestment feature.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stratton John G

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Equivalent Units	(1)	12/31/2025		A		313		(1)	(1)	Common Shares	313	$125.29	13,034(2)	D

Explanation of Responses:

1. Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

	/s/ John G. Stratton by Jessica H. Paik, Attorney-in-Fact	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Abbott Laboratories (ABT) disclose for John G. Stratton?

Abbott Laboratories reported that director John G. Stratton acquired 313 stock equivalent units on 12/31/2025 as part of his director compensation, linked to Abbott common shares.

How many Abbott Laboratories (ABT) stock equivalent units does John G. Stratton now hold?

Following the reported transaction, John G. Stratton beneficially owned 13,034 stock equivalent units tied to Abbott Laboratories common shares, held in a direct capacity.

What are the terms of the stock equivalent units reported by Abbott Laboratories (ABT)?

The stock equivalent units represent director fees credited to an account under a grantor trust and are generally paid in cash at about age 65 or upon retirement from the board. They earn the same return as if invested in Abbott shares.

At what price were the new Abbott Laboratories (ABT) stock equivalent units recorded?

The 313 stock equivalent units credited to John G. Stratton on 12/31/2025 were recorded at a derivative security price of $125.29 per unit.

Does the Abbott Laboratories (ABT) filing indicate dividend reinvestment on stock equivalent units?

Yes. The explanation notes that the reported balance of 13,034 stock equivalent units includes units acquired through a dividend reinvestment feature.

Is John G. Stratton a director or officer of Abbott Laboratories (ABT)?

The filing identifies John G. Stratton’s relationship to Abbott Laboratories as a Director, with the Form 4 checked as being filed by one reporting person.